Physician profile
Jasper Bash
NPI 1154825834
$59,138.56
in general payments reported to CMS, 2019-2025
11 companies · $2,039 in 2025
The $2,039 reported for 2025 was more than what 80% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $155 · 2021: $209 · 2022: $1,678 · 2023: $53K · 2024: $2,075 · 2025: $2,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $50K · Food and Beverage: $4,155 · Travel and Lodging: $2,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $50,000.00 |
| Food and Beverage | $4,155.48 |
| Travel and Lodging | $2,940.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $57,006.79 | 2020-2025 | General - Erectile Dysfunction, Ams 700, Tactra |
| Endo Pharmaceuticals INC. | $543.33 | 2023-2024 | Xiaflex |
| Antares Pharma, INC. | $441.35 | 2023-2025 | Xyosted, Tlando |
| Urogen Pharma, INC. | $309.62 | 2022-2024 | Jelmyto |
| Coloplast Corp | $248.66 | 2023-2025 | Titan |
| Endo USA, INC. | $217.92 | 2024-2025 | Xiaflex |
| Edap Technomed INC | $109.00 | 2023 | |
| Axonics, INC. | $94.82 | 2023 | Bulkamid |
| Astellas Pharma US INC | $70.04 | 2021 | |
| Halozyme INC | $55.78 | 2023 | |
| Innovation Technologies INC | $41.25 | 2024 | Irrisept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasper Bash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.